Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.
Trachoma cost-effectiveness of therapy
Rhinosinusitis cost-effectiveness of therapy
Hearing impairment cost-effectiveness of therapy
Bornholm disease cost-effectiveness of therapy
Esophageal cancer cost-effectiveness of therapy
Eczema cost-effectiveness of therapy
Mometasone furoate detailed information
Pulmonary nodule cost-effectiveness of therapy